Saturday 17 October 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
121.84
0.33
+0.27%
Follow HALO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 50.50 | 0.00 | 0.00 | 44.49 | 14.11 | 37.25 | 17.47 | 13.66 | 25.79 |
Piotroski F-Score |
2 | 7 | 3 | 3 | 7 | 5 | 4 | 8 | 9 | 5 |
P/S ratio |
8.71 | 8.70 | 13.83 | 13.06 | 21.74 | 12.76 | 11.43 | 5.95 | 5.97 | 5.77 |
Altman Z-Score |
(0.12) | 5.91 | 5.48 | 2.67 | 8.55 | 5.77 | 4.14 | 3.41 | 4.31 | 3.46 |
P/FCF ratio |
0.00 | 20.77 | 0.00 | 0.00 | 107.68 | 18.98 | 28.87 | 13.21 | 12.95 | 12.51 |
Altman Z″-Score (non-manufacturers) |
(4.49) | 3.26 | 0.52 | 1.23 | 0.88 | 6.54 | 3.50 | 3.93 | 5.60 | 3.02 |
Beneish M-Score |
(4.61) | (0.87) | (1.35) | (1.56) | (1.25) | 0.26 | (0.57) | (2.74) | (2.33) | (2.59) |
P/Operating CF |
(81.08) | 17.98 | 200.81 | (96.11) | 114.25 | 68.54 | 91.50 | 48.19 | 33.98 | 36.82 |
P/B ratio |
0.00 | 13.23 | 8.44 | 27.89 | 38.51 | 28.71 | 44.43 | 58.86 | 16.67 | 165.22 |
Price to Tangible BV |
0.00 | 13.23 | 8.44 | 27.89 | 38.51 | 28.71 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
8.79 | 7.86 | 12.33 | 12.96 | 23.32 | 13.06 | 13.16 | 7.39 | 6.90 | 7.72 |
EV/EBITDA |
0.00 | 29.41 | 0.00 | 0.00 | 38.40 | 20.33 | 26.64 | 14.47 | 11.13 | 19.20 |
EV/Operating CF |
(25.60) | 18.57 | (37.83) | (29.74) | 112.53 | 19.34 | 36.18 | 15.77 | 14.62 | 16.54 |
EV/FCF |
(24.10) | 18.75 | (34.58) | (28.39) | 115.50 | 19.43 | 33.25 | 16.42 | 14.96 | 16.72 |
Quick Ratio |
4.04 | 3.74 | 2.57 | 5.61 | 1.11 | 7.10 | 4.54 | 5.07 | 6.50 | 3.30 |
Current Ratio |
4.70 | 3.89 | 2.86 | 6.35 | 1.32 | 7.91 | 5.65 | 6.64 | 7.80 | 4.66 |
Net Debt/EBITDA |
(0.17) | (3.15) | 3.33 | 0.29 | 0.18 | 0.48 | 3.51 | 2.75 | 1.45 | 3.56 |
Debt/Assets |
82.83% | 38.92% | 28.71% | 71.14% | 68.50% | 79.38% | 81.79% | 86.50% | 72.97% | 84.85% |
Debt/Equity |
(6.67) | 0.97 | 0.51 | 4.39 | 2.63 | 4.45 | 8.87 | 17.89 | 4.14 | 43.89 |
Asset Turnover |
0.66 | 0.81 | 0.32 | 0.39 | 0.47 | 0.53 | 0.45 | 0.46 | 0.53 | 0.61 |
Operating CF/Net income |
0.49 | 2.13 | 0.62 | 1.18 | 0.43 | 0.74 | 1.19 | 1.38 | 1.08 | 2.06 |
Capex/Depreciation |
(0.20) | (0.37) | (5.53) | (0.99) | (0.08) | (0.16) | 0.36 | (0.18) | (0.14) | (0.08) |
Interest Coverage |
(4.17) | 3.68 | (3.84) | (5.81) | 7.08 | 36.66 | 15.79 | 17.99 | 30.48 | 25.87 |
| (1,958.98%) | 71.60% | (35.14%) | (42.41%) | 106.33% | 231.44% | 110.23% | 222.07% | 198.42% | 153.59% | |
| (46.48%) | 16.12% | (16.73%) | (14.36%) | 22.53% | 47.82% | 13.72% | 15.75% | 23.39% | 13.81% | |
ROIC |
0.00% | 0.00% | (208.92%) | (57.81%) | 50.02% | 51.83% | 12.73% | 16.92% | 27.06% | 14.31% |
Return on Tangible Assets |
(49.96%) | 16.46% | (28.09%) | (15.41%) | 89.66% | 49.24% | 29.56% | 39.72% | 43.48% | 43.39% |
Average Days of Receivables |
39.02 | 25.52 | 72.12 | 110.70 | 133.30 | 74.90 | 127.77 | 103.09 | 110.89 | 115.33 |
Research and Development Expense of Revenue |
102.83% | 47.58% | 98.94% | 71.84% | 12.79% | 8.05% | 10.09% | 9.21% | 7.79% | 26.23% |
Selling, General and Administrative Expense of Revenue |
31.26% | 17.00% | 40.04% | 39.42% | 17.09% | 11.35% | 21.74% | 17.99% | 15.20% | 14.83% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.52 | 0.51 | 0.40 | 0.62 |
Share Based Compensation of Revenue |
17.44% | 9.69% | 23.51% | 17.74% | 6.43% | 4.70% | 3.70% | 4.42% | 4.27% | 3.69% |
Graham Net Nets |
(0.03) | 0.07 | 0.11 | 0.03 | 0.02 | 0.00 | (0.12) | (0.18) | (0.10) | (0.20) |
Graham Number |
2.15 | 3.71 | 0.00 | 0.00 | 4.89 | 9.48 | 6.43 | 5.53 | 15.03 | 4.89 |
Earnings Yield |
(8.11%) | 1.98% | (3.79%) | (2.82%) | 2.25% | 7.09% | 2.68% | 5.72% | 7.32% | 3.88% |
Free Cash Flow Yield |
(4.19%) | 4.82% | (2.58%) | (3.50%) | 0.93% | 5.27% | 3.46% | 7.57% | 7.72% | 7.99% |
Revenue per Share |
1.15 | 2.32 | 1.06 | 1.36 | 1.96 | 3.15 | 4.82 | 6.29 | 8.01 | 11.65 |
Operating CF per Share |
(0.39) | 0.98 | (0.34) | (0.59) | 0.41 | 2.13 | 1.75 | 2.95 | 3.78 | 5.44 |
Capex per Share |
(0.02) | (0.01) | (0.03) | (0.03) | (0.01) | (0.01) | 0.15 | (0.12) | (0.08) | (0.06) |
Free Cash Flow per Share |
(0.42) | 0.97 | (0.38) | (0.62) | 0.40 | 2.12 | 1.91 | 2.83 | 3.69 | 5.38 |
Cash per Share |
1.60 | 3.44 | 2.47 | 2.92 | 2.70 | 5.27 | 2.65 | 2.55 | 4.70 | 1.19 |
Shareholders Equity per Share |
(0.25) | 1.53 | 1.73 | 0.64 | 1.11 | 1.40 | 1.24 | 0.64 | 2.87 | 0.41 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.25) | 1.53 | 1.73 | 0.64 | 1.11 | 1.40 | 1.24 | 0.64 | 2.87 | 0.41 |
Free Cash Flow |
(53.52) | 132.70 | (54.16) | (89.46) | 54.03 | 297.98 | 261.31 | 373.28 | 468.37 | 644.59 |
Working Capital |
201.95 | 379.04 | 278.49 | 457.80 | 133.38 | 809.14 | 608.22 | 633.93 | 946.24 | 648.12 |
Capital Expenditures |
(3.14) | (1.35) | (4.66) | (4.04) | (1.43) | (1.46) | 21.20 | (15.29) | (10.70) | (6.97) |
Net Current Asset Value |
(37.46) | 198.79 | 236.49 | 69.33 | 125.89 | 18.81 | (932.70) | (903.04) | (614.32) | (1,651.30) |
EV/EBIT |
0.00 | 30.73 | 0.00 | 0.00 | 43.26 | 20.99 | 32.47 | 18.15 | 12.70 | 22.98 |
Capex to Sales |
0.02 | 0.00 | 0.03 | 0.02 | 0.01 | 0.00 | (0.03) | 0.02 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 34.02 | 0.00 | 0.00 | 40.33 | 20.50 | 28.20 | 14.61 | 11.00 | 17.20 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.66 | 1.03 | 0.11 | 0.38 | 1.72 | 1.01 | 0.78 | 1.15 | 1.04 | 1.12 |
Cash ROIC |
(13.75%) | 15.08% | (7.42%) | (9.77%) | 5.90% | 16.42% | 12.82% | 19.45% | 19.00% | 27.61% |
Accounts Receivable Turnover |
6.10 | 16.75 | 5.83 | 4.38 | 3.41 | 4.70 | 4.10 | 3.56 | 3.74 | 3.73 |
Accounts Payable Turnover |
8.22 | 5.41 | 1.69 | 8.66 | 10.37 | 46.94 | 14.49 | 13.04 | 14.45 | 14.69 |
Inventory Turnover |
2.75 | 3.15 | 0.73 | 1.75 | 0.96 | 1.42 | 1.81 | 1.69 | 1.18 | 1.44 |
Average Days of Payables |
39.33 | 93.12 | 146.89 | 51.56 | 16.23 | 6.91 | 46.36 | 22.42 | 23.47 | 33.34 |
Days of Inventory on Hand |
160.74 | 60.29 | 814.73 | 235.28 | 511.28 | 241.69 | 262.34 | 242.12 | 324.80 | 281.56 |
Average Receivables |
24.05 | 18.91 | 26.07 | 44.72 | 78.59 | 94.35 | 161.02 | 232.64 | 271.33 | 374.86 |
Average Payables |
4.04 | 5.76 | 6.01 | 5.26 | 4.18 | 1.73 | 9.62 | 14.75 | 11.03 | 15.57 |
Average Inventory |
12.06 | 9.88 | 13.89 | 25.99 | 45.05 | 57.33 | 77.02 | 113.86 | 134.73 | 159.17 |
Average Assets |
221.65 | 390.73 | 480.10 | 503.06 | 572.90 | 842.18 | 1,472.97 | 1,787.39 | 1,898.37 | 2,294.40 |
Average Common Equity |
5.26 | 87.94 | 228.63 | 170.33 | 121.41 | 174.00 | 183.38 | 126.80 | 223.81 | 206.32 |
Columns are period end dates